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ABSTRACT 
 
Background 
Topical corticosteroids (CS) are commonly used to treat inflammatory skin conditions including 
eczema and psoriasis. While topical CS package inserts describe hyperglycaemia and glycosuria as 
adverse drug reactions, it is unclear whether topical CS use in real life is also associated with an 
increased risk of type 2 diabetes (T2D). 
 
Methods 
Two matched case-control studies and one cohort study were conducted using routinely collected 
healthcare data from Denmark the UK. A total of 115,218 and 54,944 adults were identified as cases 
with new onset T2D in the Danish and UK case-control study, respectively. For the Danish cohort 
study, 2,689,473 adults were included. The main exposure was topical CS and the outcome was 
incident T2D.  
 
Results 
Topical CS was significantly associated with T2D in the Danish (adjusted OR 1ꞏ35; 95% CI 1ꞏ33-
1ꞏ38) and UK (adjusted OR 1ꞏ23; 95% CI 1ꞏ19-1ꞏ27) case-control studies. Individuals who were 
exposed to topical CS had significantly increased risk of incident T2D (adjusted HR 1ꞏ27; 95% CI 
1ꞏ26-1ꞏ29). We observed significant dose-response relationships between T2D and increasing potency 
of topical CS in the two Danish studies. The results were consistent across all sensitivity analyses.  
 
Conclusions 
We found a positive association between topical CS prescribing and incident T2D in Danish and UK 
adult populations. Clinicians should be cognizant of possible diabetogenic effects of potent topical 
CS.   
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INTRODUCTION 
 
Topical corticosteroids (CS) are widely used to treat chronic inflammatory and pruritic skin 
conditions such as psoriasis and eczema due their efficacy, moderate costs, and relatively good safety-
profile.1 However, topical CS are small molecules that can get absorbed into the skin and ultimately 
reach the systemic circulation and cause internal exposure.2 According to the Summary of Product 
Characteristics (SmPC), systemic toxicity is common and hyperglycaemia and glucosuria are well-
established side effects following topical CS use.3 Since most physicians are aware of the numerous 
serious side-effects of prolonged systemic CS use, e.g. type 2 diabetes (T2D), these are often 
prescribed with caution and for the shortest amount of time necessary. Topical CS were initially 
developed primarily for short-term use, but long-term maintenance therapy are now recommended in 
many dermatological guidelines.4–9 Concern has previously been raised about similar diabetogenic 
effects with use of topical CS, but this risk remains unclear and is therefore not considered by most 
physicians.10,11   
 
We performed three large pharmaco-epidemiological studies based on data from two European 
countries to investigate the association between topical CS use and risk of new-onset T2D in adults.  
 
METHODS 
Study design and setting 
Two matched nested case-control studies in Denmark and the United Kingdom (UK), respectively, 
where the outcome was newly diagnosed T2D and the exposure was topical CS use. Furthermore, we 
performed a cohort study in the Danish population in time-to-event analyses. Data for the Danish 
studies were extracted from the Danish nationwide healthcare and administrative registries, which 
contain information on all hospital contacts, dispensed medication from all pharmacies, as well as 
social and demographic data on the entire population.12,13 The UK study was conducted based on the 
Clinical Practice Research Datalink (CPRD), a large primary health-care database including clinical 
data from general practitioners.14 Individuals with diabetes-related drugs or diagnostic codes before 
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study start were excluded from all study cohorts to enable identification of new-onset T2D. Patients 
with polycystic ovary syndrome, pancreatic cancer, and chronic pancreatitis during the entire study 
period were excluded to avoid misclassification of the outcome variable. The study covariates were 
selected based on possible confounding effects in terms of the exposure and outcome. As the available 
data differed in the two data sources we used proxies as replacements (e.g. missing BMI data in the 
Danish cohort was replaced by antihypertensive drugs, lipid lowering drugs and socioeconomic status, 
to represent the burden of obesity). A detailed description of study design, methodology and 
sensitivity analyses is available as supplementary materials.  
 
The Danish case-control study 
The entire Danish population aged ≥18 years from January 1st 2007 through December 31st 2012 
served as the source population. All individuals with at least one filled prescription of a non-insulin 
antidiabetic drug were included as cases on the date of their first such prescription (index date), and 
matched with the same number of controls without any diabetes, based on age and sex. Cases and 
controls had the same age on the day they were included. Exposure to topical CS in a period of four 
years prior to the index date was identified. Topical CS prescriptions during the study period were 
presented as a binary variable of never/ever exposure prior to the index date. Topical CS exposure 
was further categorized by potency for each participant, where a prescription of a more potent 
preparation overruled a less potent preparation. The four potency categories were based on WHO’s 
classification of drugs into mild (e.g. hydrocortisone), moderate (e.g. hydrocortisone-17-butyrate), 
potent (e.g. mometasone furoate), and very potent topical CS (e.g. clobetasol proprionate). Duration 
of use was classified based on the prescription dates. Long-term use was defined as prescriptions in 
two consecutive years or more. Current use was defined as a prescription in the year prior to index. In 
comparative analyses, topical calcineurin inhibitors (an alternative anti-inflammatory topical 
medication) were used as a negative control. The selected covariates for the Danish study were 
systemic CS (oral or injections), inhaled corticosteroids (for oral inhalation), antihypertensive drugs, 
lipid lowering drugs, smoking, alcohol abuse, socioeconomic status, and psoriasis. Psoriasis was 
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included as a covariate, as topical CS are often used to treat the conditions which is known to be 
associated with T2D.15 
 
The UK case-control study 
The source population were individuals aged 26-89 years recorded in the CPRD between January 1st 
2007 and December 31st 2015. Patients aged between 30 and 89 with a first diabetes diagnosis (non-
specific diabetes or T2D), with no prior prescription of insulin and never coded with type 1 diabetes 
(T1D), were identified as cases. Cases were matched with the same number of controls with the same 
age at inclusion, sex and GP practice, who were selected from people without any diagnostic or drug 
code compatible with any diabetes. Exposure to topical CS was defined as described in the previous 
paragraph. The covariates in the UK cohort were systemic CS (oral or injections), body mass index 
(BMI), smoking status, psoriasis, eczema, and orally inhaled CS.  
 
The Danish cohort study 
The source population was defined as all Danish citizens aged ≥18 years from January 1st 2001 
through December 31st 2015. Individuals with any diagnostic code or drug code for any diabetes or 
any prescriptions of antidiabetic drugs and/or topical CS before study start were excluded. Topical CS 
exposure was modelled as a time-varying variable, where exposure status changed from ‘unexposed’ 
to ‘exposed’ on the day of the first filled prescription. Similarly, potency of topical CS was modelled 
as a time-varying exposure variable. The outcome was defined as the first filled prescription of a non-
insulin antidiabetic drug. Individuals were followed from study inclusion (January 1st 2001 or 18th 
birthday after this date) and censored at the occurrence of the outcome, migration, death, or December 
31, 2015 whichever came first. In sensitivity analyses we used renal cancer as a neutral outcome. The 
selected covariates were age, sex, smoking, alcohol abuse, systemic CS, inhaled CS, antihypertensive 
drugs, lipid-lowering drugs, socioeconomic status, and psoriasis.  
 
Statistical analysis 
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Categorical variables were presented as frequencies with percentages and continuous variables as means 
with standards deviations (SD). Multivariable conditional logistic regression was used to calculate 
crude and adjusted odds ratios (aORs) modelling T2D as a dichotomous outcome variable in the case-
control studies. We adjusted for confounders, as specified previously. Matching variables were not 
included in the models. Wald and likelihood ratio tests were used to investigate significance. Trend 
tests were performed for ordered categorical variables. In the cohort study we applied Cox regression 
models to estimate crude and adjusted hazard ratios (HRs). Nelson-Aalen cumulative hazards curves 
were presented to illustrate the risk over time. Results were presented with 95% confidence intervals 
(CIs) where applicable, and p-values less than 0ꞏ05 were considered statistically significant. STATA 
v13ꞏ0 (StataCorp, College Station, TX, USA) and SAS v9ꞏ4 (SAS Institute Inc. Cary, NC, USA) were 
used.  
 
RESULTS  
 
The Danish case-control study 
A total of 115,218 individuals were identified as cases (new onset T2D) and matched with an identical 
number of controls in the Danish population. The mean age (SD) in the two groups was 61ꞏ9 (15ꞏ1) 
years with a slight male predominance (53ꞏ8%) (Table 1). The T2D group had a lower income level 
and higher prevalence of comorbidities. The prevalence of having at least one claimed topical CS and 
systemic CS prescriptions during the study period were higher among cases (34ꞏ2% and 15ꞏ5%) than 
controls (26ꞏ9% and 11ꞏ0%).  
 
Primary analysis showed a significant and positive association between T2D and topical CS in crude 
(OR 1ꞏ41; 95% CI 1ꞏ39-1ꞏ44) and fully adjusted analyses (aOR 1ꞏ25; 95% CI 1ꞏ23-1ꞏ28) (Table 2). 
Similarly, T2D was associated with systemic CS in crude (OR 1ꞏ49; 95% CI 1ꞏ45-1ꞏ53) and adjusted 
analyses (aOR 1ꞏ28; 95% CI 1ꞏ23-1ꞏ32). In analyses of topical CS potency, the association followed a 
dose-response pattern where very potent topical CS showed the strongest association (aOR 1ꞏ33; 95% 
CI 1ꞏ27-1ꞏ40) followed by potent (aOR 1ꞏ26; 95% CI 1ꞏ22-1ꞏ29), moderate (aOR 1ꞏ22; 95% CI 1ꞏ17-
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1ꞏ27) and mild (aOR 1ꞏ17; 95% CI 1ꞏ07-1ꞏ28) topical CS, with a significant p-value for trend 
<0ꞏ0001. Analyses of exposure duration and latency showed that current long-term use of topical CS, 
i.e. 2 consecutive years (aOR 1ꞏ36; 95% CI 1ꞏ30-1ꞏ42) and current short-term use, i.e. within past 
year (aOR 1ꞏ30; 95% CI 1ꞏ25-1ꞏ36) were associated with T2D. Estimates for former use were weaker, 
but still significant. Sensitivity analyses yielded similar results (Table S1, S2, S3). No association was 
found between T2D and use of topical calcineurin inhibitors (aOR 0ꞏ92; 95% CI 0ꞏ84-1ꞏ01) (Table 
S8). 
 
The UK case-control study 
 
In the UK cohort, we identified 54,944 patients with T2D and matched controls, respectively. The 
fraction of male participants was 56ꞏ3% and the mean age (SD) was 62ꞏ1 (12ꞏ6) in both groups. BMI 
was higher in patients with T2D compared with controls. The prevalence of current smoking was 
similar in the two groups. Overall, 38ꞏ2% of all cases and 29ꞏ5% of controls had at least one 
prescription of topical CS during the study period. Prescriptions for systemic CS occurred in 21ꞏ7% of 
cases and 14ꞏ9% of controls.  
 
Exposure to topical CS was significantly associated with T2D in crude (OR 1ꞏ46; 95% CI 1ꞏ42-1ꞏ50) 
and adjusted (aOR 1ꞏ23; 95% CI 1ꞏ19-1ꞏ27) analyses (Table 3). The association between T2D and 
systemic CS use was also significant, and slightly stronger than for topical CS (aOR 1ꞏ33; 95% CI 
1ꞏ27-1ꞏ38). As opposed to the Danish study, topical CS potency as a categorical variable showed no 
significant trend in terms of association with T2D. Exposure to mild topical CS (aOR 1ꞏ27; 95% CI 
1ꞏ21-1ꞏ33) and very potent topical CS (aOR 1ꞏ32; 95% CI 1ꞏ21-1ꞏ44) yielded similar estimates, while 
moderately potent topical CS (aOR 1ꞏ19; 1ꞏ11-1ꞏ27) and potent topical CS (aOR 1ꞏ20; 95% CI 1ꞏ14-
1ꞏ25) were slightly lower. The estimates for current short-term use were strongest (aOR 1ꞏ38; 95%CI 
1ꞏ31-1ꞏ45) followed by current long-term use (aOR 1ꞏ26; 95% CI 1ꞏ19-1ꞏ34). Former use of topical 
CS showed slightly lower effect measurements. After excluding patients with a first-time prescription 
within 30 and 90 days, respectively, prior to index date, the effect measurement between topical CS 
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and T2D became lower than in primary analysis, but remained statistically significant (aOR 1ꞏ19; 
95% CI 1ꞏ14-1ꞏ23) (Table S5). The results from the remaining sensitivity analyses are available in 
supplementary files (Table S4, S6, S7, S8). There was no evidence of effect modification between 
BMI and topical CS in terms of T2D risk. In comparative analyses, T2D was not associated with 
topical calcineurin inhibitor use (aOR 1ꞏ00; 95% CI 0ꞏ79-1ꞏ27) (Table S9).  
 
The Danish cohort study 
A total of 4,241,772 individuals served as the source population. We excluded 123,253 individuals 
with any previous diabetes and 1,404,238 individuals with topical CS prescriptions prior to study 
start. 24,808 individuals were excluded due to exclusion diagnoses (PCOS, pancreatic cancer, and 
pancreatitis), yielding a total study population of 2,689,473 individuals. During the study period 
1,051,080 (39ꞏ1%) individuals claimed at least one prescription of topical CS. The mean age (SD) 
was 46ꞏ6 (17ꞏ2) years at study inclusion, with a similar gender distribution among exposed 
individuals. Overall, the topical CS exposed group had higher prevalence of comorbidities and co-
prescribed medication compared with unexposed individuals.  
 
The incidence rates (95% CI) of T2D were 5ꞏ73 (5ꞏ68-5ꞏ78) and 3ꞏ56 (3ꞏ54-3ꞏ58) per 1000 person-
years among topical CS exposed and unexposed individuals, respectively, yielding an absolute risk 
difference of 2ꞏ17 (2ꞏ15-2ꞏ19) per 1000 person years (Table 3). In context, the absolute risk difference 
for systemic CS was 2ꞏ67 (2ꞏ65-2ꞏ69). Cox regression models yielded an age and sex-adjusted HR of 
1ꞏ34 (1ꞏ32-1ꞏ36) and a fully adjusted HR of 1ꞏ27 (1ꞏ26-1ꞏ29) when topical CS was modelled as a 
binary exposure variable and T2D as outcome (Table 4). We assessed the risk of T2D according to the 
potency of topical CS exposure and found a dose-response relationship similar to the Danish case-
control study results. Adjusted estimates for mild (aHR 1ꞏ09; 95% CI 1ꞏ05-1ꞏ14) was followed by 
moderate (aHR 1ꞏ21; 95% CI 1ꞏ18-1ꞏ23), potent (1ꞏ30; 95% CI 1ꞏ28-1ꞏ31), and very potent topical 
CS (1ꞏ39; 95% CI 1ꞏ35-1ꞏ42), respectively. When analysing the data according to different age 
groups, we found the highest HR for T2D due to topical CS use in the age group 40-49 years, as seen 
in Table S13 and Figure 2. In analyses where renal cancer was modelled as a negative control, no 
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significant dose-response relationship was observed (Table S18). Furthermore, in a subgroup analysis 
of participants who had never received treatment with systemic CS, the results remained virtually 
unchanged (Table S19). In addition, we performed sensitivity analyses where patients were required 
to have multiple prescriptions of topical CS to be considered exposed, i.e. where patients only 
receiving one single prescription of topical CS during the study period were excluded. In such 
analyses, the effect estimates were comparable to our primary analysis, and all results remained 
statistically significant (data not shown). In landmark analyses, we observed that potent topical CS 
was the only significant predictor for T2D within 6 months after first-time exposure (Table S14), 
while all potencies were significantly associated with T2D risk long-term. Nelson-Aalen cumulative 
hazards curves showed overall linear curves (Figure 1 and S1).  
 
DISCUSSION 
 
Main findings  
We found a positive and significant association between exposure to topical CS and new-onset T2D in 
two large population-based European adult cohorts. Moreover, a dose-dependent relationship was 
found between potency of prescribed topical CS and T2D in the two Danish studies. Exposure to 
systemic CS and topical CS exposure represented a similar excess risk of approximately two more 
cases of T2D per 1000 persons per year.  
 
Interpretation 
These three studies of Danish and UK adults showed that topical CS are very frequently prescribed, 
highlighting the importance of safety assessments of these drugs. The UK register contained 
prescriptions given by general practitioners only, whereas the Danish register also contained 
prescriptions given by dermatologists who see patients with more chronic and severe disease, which 
require extensive and prolonged topical CS treatment. Along this line, milder potencies of topical CS 
were used more frequently in the UK study, whereas higher potencies were used more frequently in 
the Danish studies. When first developed, topical CS were intended only as short-term therapy, and 
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their SmPC explicitly state that “systemic toxicity is common especially following long continued use 
on large areas of damaged skin, in flexures and with polythene occlusion”.3 Typically, dermatologists 
use potent or very potent topical CS in patients with extensive and moderate-to-severe inflammatory 
skin diseases such as psoriasis, eczema, lichen planus, and bullous pemphigoid and for long periods as 
these are chronic diseases. Accordingly, Danish and international guidelines for eczema and psoriasis 
treatment include recommendations of using moderately potent topical CS daily until resolution and 
then replaced by twice-weekly application as long-term maintenance treatment.4–9 Interestingly, 
increased occurrence of T2D have been reported in patients with psoriasis and atopic dermatitis in 
some but not all studies, which in part could be explained by the chronic and widespread use of 
topical CS.16,17  
 
In sensitivity analyses of UK data, we observed that the effect measurements became substantially 
lower when participants with recent topical CS prescriptions prior to T2D diagnosis were excluded 
(Table S5), suggesting possible surveillance bias. Similar indications of surveillance bias were 
observed in another CPRD study that investigated statin use and the risk of T2D.18 Therefore, our 
analysis, which excluded people with a recent topical CS prescription prior to diagnosis of T2D 
(Table S5), may be less influenced by surveillance bias and represent a more accurate assessment of 
the true association than the primary analysis of the UK data. In the Danish cohort study, we observed 
signs of possible surveillance bias after first-time use of potent topical CS in landmark analyses. 
Potent (but not very potent) topical CS are typically used as the first-line treatment of unspecified 
inflammatory skin rash on the body, and blood samples may be a part of the initial diagnostic work-
up, thereby increasing the chances of detecting already existing T2D. However, in Nelson-Aalen 
cumulative hazards curves, we observed that the risk of T2D was constant over time and not isolated 
immediately after the first-time exposure. Indeed, this finding was corroborated by our landmark 
analyses, suggesting that the findings cannot be explained solely by surveillance bias. We performed 
comparative analyses with topical calcineurin inhibitor use in both cohorts and found no association 
with T2D. Furthermore, we did not observe an increased risk of renal cancer following topical CS use 
in time-to-event analysis; a condition that is associated with itch and therefore may be treated with 
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topical CS. This supports the notion that the results indicate a true association between topical CS and 
T2D, and are not driven by bias alone. 
 
Our findings are in accordance with a large Dutch study that showed a significant association between 
topical CS and T2D (OR 1ꞏ27; 95% CI 1ꞏ10-1ꞏ47).11 However, another UK-based study with data 
from The Health Improvement Network (THIN) registry found no association.10 The discrepancies in 
the results could partially be due to methodological differences. The THIN study was propensity 
score-matched, based on smoking, BMI and 20 classes of comorbidity and 15 classes of co-prescribed 
medication; possibly a more conservative approach that would tend to underestimate a true effect. 
From a mechanistic perspective, the observed association may be explained by trans-epidermal 
absorption of topical CS that could influence glucose metabolism. Hyperglycaemia and glucosuria are 
indeed adverse drug reactions described in patient information leaflets of topical CS.3,19 Clinical 
studies have reported adrenal suppression induced by topical CS, suggesting that prolonged and 
excessive use could impact T2D risk.20,21 Furthermore, glucosuria and hyperglycaemia have been 
measured following topical CS application in patients with psoriasis.22 The molecular weight of 
topical CS is less than 500 Dalton, i.e. the pragmatic upper limit for a molecule to penetrate the 
epidermal barrier.2 In contrast, the molecular weight of topical calcineurin inhibitors is over 800 
Dalton and its use was not associated with T2D.23 Furthermore, lesional skin in conditions such as 
eczema displays a 2-5 fold higher absorption rate compared with intact skin, indicating that patients 
with chronic severe skin conditions may be at higher risk of systemic adverse effects.24 No large 
studies have to our knowledge examined glucose levels or insulin resistance in patients treated with 
topical CS, however a number of smaller exposure studies have suggested systemic metabolic 
changes following topical CS exposure, including suppression of the hypothalamic-pituitary-adrenal 
axis.20,25–30  
 
Strengths and limitations 
We found similar results in two large data sets from two countries. The Danish cohort study 
confirmed the association in time-to-event analysis securing the chronology between the exposure and 
13 
 
outcome. The Danish registries and the CPRD are recognized for their high data quality and 
representativeness. Despite the high quality, some misclassification of the variables may have 
occurred, due to limited validation studies. Importantly, in the current study we used drug prescription 
codes to identify cases with T2D, as complete information on clinical measurements such as 
hyperglycaemia in the studied populations were not available. Due to the prospective data collection, 
there is virtually no risk of recall bias.14,31 We controlled for important confounding factors, however, 
residual confounding cannot be excluded. Furthermore, reverse causality could have influenced our 
results since patients with pre-diabetes or undiagnosed diabetes could use more topical CS due to 
increased incidence of dry skin, itch, along with bacterial and fungal infections in turn leading to 
false-positive associations.32–34 However, itch is also a symptom of renal cancer, but here we observed 
no association. Poor treatment adherence and fluctuating symptoms in chronic skin diseases may 
influence the use of topical CS and it was impossible to estimate the frequency, time, and true amount 
of applied topical CS per patient. Absorption rates of topical CS are influenced by the anatomical 
regions of the skin, however, this information was unavailable. Although we used topical calcineurin 
inhibitors as a control marker, these drugs are usually not first-line treatment and their indications are 
more restricted than topical CS. Prescriptions from secondary care were unavailable in the UK study, 
however the vast majority of topical CS are prescribed in primary care, and sensitivity analyses 
indicated that the lack of such data did not bias the results substantially. Importantly, these studies 
were limited to adults.  
 
 
CONCLUSION 
 
In three large population-based studies, use of topical CS in adults was significantly associated with 
risk of T2D. Clinicians should be cognizant of possible diabetogenic effects of high-potency topical 
CS and consider other treatment options if possible.   
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Table 1. Population characteristics of the three studies 
 
  Danish case‐control study  UK case‐control study    Danish cohort study 
  Cases (T2D)  Controls  (no T2D)  Cases (T2D)  Controls (no T2D)    Exposed  (topical CS use) Unexposed (no topical CS use)
  n=115,218 (50)  n=115,218 (50)  n=54,944 (50)  n=54,944 (50)    n=1,051,080 (39∙1)  n=1,638,393 (60∙9) 
     
Gender     
Male (%)  61994 (53∙8)  61994 (53∙8)  30936 (56∙3)  30936 (56∙3)    517929 (49∙3)  917672 (56∙1) 
Female (%)  53224 (46∙2)  53224 (46∙2)  24008 (43∙7)  24008 (43∙7)    533151 (50∙7)  719721 (43∙9) 
     
Age     
Mean (SD)  61∙9 (15∙1)  61∙9 (15∙1)  62∙1 (12∙6)  62∙1 (12∙6)    46∙6 (17∙2)  46∙2 (17∙9) 
Median (q25, q75)  63∙8 (52∙8, 72∙4)  63∙8 (52∙8, 72∙4)  63∙0 (53, 72)  63∙0 (53, 72)    45∙9 (32∙4, 58∙8)  43∙9 (31∙8, 57∙7) 
     
BMI     
Mean (SD)  n/a  n/a  32∙3 (5∙30)  27∙3 (6∙78)    n/a  n/a 
Median (q25, q75)  n/a  n/a  31∙3 (27∙7, 35∙9)  26∙6 (23∙8, 30∙0)    n/a  n/a 
     
BMI categories     
<18∙5  n/a  n/a  231 (0∙42)  941 (1∙71)    n/a  n/a 
18∙5‐25  n/a  n/a  5487 (9∙99)  16746 (30∙5)    n/a  n/a 
25‐30  n/a  n/a  16229 (29∙5)  19715 (35∙9)    n/a  n/a 
30‐40  n/a  n/a  25729 (46∙8)  11421 (20∙8)    n/a  n/a 
>40  n/a  n/a  6623 (12∙1)  1223 (2∙23)    n/a  n/a 
Missing  n/a  n/a  645 (1∙2)  4898 (8∙9)    n/a  n/a 
     
Smoking     
     
Current smoker  n/a  n/a  9390 (17∙1)  9390 (17∙0)    n/a  n/a 
Non‐smoker  n/a  n/a  26055 (47∙4)  29085 (52∙9)    n/a  n/a 
Ex‐ smoker  n/a  n/a  19370 (35∙3)  15284 (27∙8)    n/a  n/a 
Missing  n/a  n/a  129 (0∙2)  1255 (2∙3)    n/a  n/a 
     
Alcohol abuse¤  7829 (6∙8)  5847 (5∙1)  n/a  n/a    69163 (6∙6)  98493 (6∙0) 
Tobacco use¤  19089 (16∙6)  12432 (10∙8)  n/a  n/a    166388 (15∙8)  197109 (12∙0) 
     
Tax reported income level     
Lowest  24637 (21∙4)  21450 (18∙6)  n/a  n/a    191284 (18∙2)  346614 (21∙2) 
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Below average  26090 (22∙6)  19997 (17∙4)  n/a  n/a    211975 (20∙2)  325913 (19∙9) 
Average  24555 (21∙3)  21533 (18∙7)  n/a  n/a    216947 (20∙6)  320948 (19∙6) 
Above average  21,947 (19∙1)  24140 (21∙0)  n/a  n/a    209019 (19∙9)  328879 (20∙1) 
Highest  17989 (15∙6)  28098 (24∙4)  n/a  n/a    221855 (21∙1)  316039 (19∙3) 
     
     
Eczema *  n/a  n/a  9558 (17∙4)  9117 (16∙6)    n/a  n/a 
Psoriasis *  5231 (4∙5)  3869 (3∙4)  2928 (5∙3)  2423 (4∙4)    35848 (3∙4)  7571 (0∙5) 
     
Anti‐hypertensive drugs  35,713 (31∙0)  18,369 (15∙9)  n/a  n/a    244615 (23∙3)  271855 (16∙6) 
Lipid‐lowering drugs  76,048 (66∙0)  25,224 (21∙9)  n/a  n/a    271184 (25∙8)  289418 (17∙7) 
Systemic corticosteroids  17,868 (15∙5)  12,720 (11∙0)  11940 (21∙7)  8163 (14∙9)    284531 (27∙1)  285267 (17∙4) 
Inhaled corticosteroids  7,187 (6∙2)  5,284 (4∙6)  8127 (14∙8)  5807 (10∙6%)    111125 (10∙6)  114162 (7∙0) 
   Population characteristics presented as n (%) if not otherwise specified. Cases were defined as patients with type 2 diabetes and controls were individuals without. The column of exposed  
BMI, body mass index; CS, topical corticosteroids; SD, standard deviation; T2D, type 2 diabetes; q25, q75, interquartile ranges 
* For participants with both diagnoses (n=1834), the last recorded diagnosis is used 
¤ Based on composite data retrieval algorithm 
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Table 2. Association between exposure to topical corticosteroids and new onset type 2 diabetes in Denmark and UK, results of two case-control studies. 
  Danish case‐control study    UK case‐control study 
          Crude    Adjusted*            Crude    Adjusted ¤ 
         
  Cases, n (%)  Controls, n(%) OR  95% CI  p‐value  OR  95% CI  p‐value    Cases, n (%)  Controls, n(%) OR  95% CI  p‐value  OR  95% CI  p‐value 
         
Exposure to topical CS  39364 (34∙2)  31010 (26∙9)  1∙41 1∙39‐1∙44 <0∙0001  1∙25 1∙23‐1∙28 <0∙0001    21009 (38∙2) 16194 (29∙5)   1∙46 1∙42‐1∙50 <0∙0001 1∙27 1∙23‐1∙31  <0∙0001 
Exposure to systemic CS 17868 (15∙5)  12720 (11∙0)  1∙49 1∙45‐1∙53 <0∙0001  1∙28 1∙23‐1∙32 <0∙0001    11940 (21∙7) 8163 (14∙9)  1∙59 1∙54‐1∙64 <0∙0001 1∙30 1∙25‐1∙35  <0∙0001 
         
Potency    <0∙0001 # <0∙0001 #       
Mild  1676 (1∙45)  1436 (1∙25)  1∙30 1∙21‐1∙39 <0∙0001  1∙17 1∙07‐1∙28 <0∙0001    7012 (12∙8)  5354 (9∙74)  1∙47 1∙42‐1∙53 <0∙0001 1∙30 1∙24‐1∙37  <0∙0001 
Moderate  8509 (7∙39)  7145 (6∙20)  1∙32 1∙28‐1∙37 <0∙0001  1∙22 1∙17‐1∙27 <0∙0001    3352 (6∙10)  2701 (4∙92)  1∙39 1∙32‐1∙47 <0∙0001 1∙22 1∙14‐1∙30  <0∙0001 
Potent  21980 (19∙1)  17279 (15∙0)  1∙42 1∙39‐1∙45 <0∙0001  1∙26 1∙22‐1∙29 <0∙0001    8659 (15∙8)  6720 (12∙2)  1∙46 1∙40‐1∙51 <0∙0001 1∙23 1∙18‐1∙29  <0∙0001 
Very potent  7199 (6∙25)  5150 (4∙47)  1∙56 1∙50‐1∙62 <0∙0001  1∙33 1∙27‐1∙40 <0∙0001    1986 (3∙61)  1419 (2∙58)  1∙58 1∙47‐1∙70 <0∙0001 1∙38 1∙26‐1∙49  <0∙0001 
         
Duration/ latency         
Former short use  20443 (17∙7)  17033 (14∙8)  1∙34 1∙31‐1∙37 <0∙0001  1∙20 1∙17‐1∙24 <0∙0001    4299 (7∙82)  3012 (5∙48)  1∙30 1∙26‐1∙35 <0∙0001 1∙17 1∙13‐1∙22  <0∙0001 
Current short use  9263 (8∙04)  7113 (6∙17)  1∙45 1∙40‐1∙50 <0∙0001  1∙30 1∙25‐1∙36 <0∙0001    6513 (11∙85) 4441 (8∙08)  1∙64 1∙58‐1∙71 <0∙0001 1∙43 1∙36‐1∙51  <0∙0001 
Former long use  1572 (1∙36)  1225 (1∙06)  1∙44 1∙33‐1∙55 <0∙0001  1∙23 1∙12‐1∙36 <0∙0001    692 (1∙26)  535 (0∙97)  1∙46 1∙30‐1∙64 <0∙0001 1∙17 1∙02‐1∙34  0∙021 
Current long use  8086 (7∙02)  5639 (4∙89)  1∙61 1∙55‐1∙66 <0∙0001  1∙36 1∙30‐1∙42 <0∙0001    9505 (17∙3)  8206 (14∙9)  1∙62 1∙54‐1∙71 <0∙0001 1∙31 1∙23‐1∙39  <0∙0001 
                                                             
          
Multivariable conditional logistic regression analysis was performed to estimate the association between exposure to topical CS and type 2 diabetes.  
Long term use of topical CS was defined as prescriptions in two consecutive years or more, and current use was defined as a prescription less than one year prior to index. No exposure was used as the reference.  
Likelihood ratio tests for categorical variables were <0.001. 
* Adjusted for systemic CS, socioeconomic status, smoking, alcohol abuse, anti-hypertensive drugs, lipid-lowering drugs, inhaled corticosteroids, and psoriasis. In analyses where systemic CS was the main predictor 
models were adjusted for topical CS. 
¤ Adjusted for systemic CS, smoking status, body mass index, inhaled corticosteroids, psoriasis, and eczema. In analyses where systemic CS was the main predictor models were adjusted for topical CS. Patients with 
missing smoking status (1.26% of study population) were excluded. Multiple imputations were used for body mass index.  
# p-value for trend test 
CI, confidence interval; CS, corticosteroids; OR, odds ratio; systemic CS, systemic corticosteroids.  
23 
 
Table 3. Incidence rates of type 2 diabetes per 1000 person-years in the Danish cohort study 
  
Follow‐up time in 
years  Events 
Incidence rate
per 1000 PY  95% CI 
 
No topical CS exposure  27051346  96273  3∙56  3∙54‐3∙58 
Any topical CS exposure  8172709  46806  5∙73  5∙68‐5∙78 
Mild topical CS  469399  2062  4∙39  4∙21‐4∙59 
Moderate topical CS  2382807  11788  4∙95  4∙86‐5∙04 
Potent topical CS  4289682  25887  6∙03  5∙96‐6∙11 
Very potent topical CS  1030820  7069  6∙86  6∙70‐7∙02 
         
No systemic CS exposure 
Any systemic CS exposure  2754275  18177  6∙60  6∙50‐6∙70 
No topical CS exposure, by age‐groups 
<30  2620134  1578  0∙60  0∙57‐0∙63 
30  5348455  5221  0∙98  0∙95‐1∙00 
40  5903227  12334  2∙09  2∙05‐2∙13 
50  5450538  23183  4∙25  4∙20‐4∙31 
60  4180552  28475  6∙81  6∙73‐6∙89 
70  3548438  25482  7∙18  7∙09‐7∙27 
Any topical CS exposure, by age‐groups         
<30  464185  661  1∙42  1∙32‐1∙54 
30  1508550  2712  1∙80  1∙73‐1∙87 
40  1622123  5622  3∙47  3∙38‐3∙56 
50  1547443  10325  6∙67  6∙54‐6∙80 
60  1499321  13796  9∙20  9∙05‐9∙36 
70  1531089  13690  8∙94  8∙80‐9∙09 
              
 
CI, confidence interval; CS, corticosteroids; PY, person-years. 
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Table 4. Cox multivariable regression models of the Danish cohort study 
Multivariable model, topical CS exposure  Multivariable model, by topical CS potency   
   
Predictor     HR    95% CI    P‐value     Predictor     HR    95% CI    P‐value 
      Topical CS potency 
Topical CS    1∙27  1∙26‐1∙29  <0∙0001      Mild  1∙09  1∙05‐1∙14  <0∙0001 
          Moderate  1∙21  1∙18‐1∙23  <0∙0001 
          Potent  1∙30  1∙28‐1∙31  <0∙0001 
          Very potent  1∙39  1∙35‐1∙42  <0∙0001 
     
Age    1∙03  1∙03‐1∙03  <0∙0001  Age  1∙03  1∙03‐1∙03  <0∙0001 
Sex     1∙50  1∙49‐1∙52  <0∙0001  Sex   1∙50  1∙49‐1∙52  <0∙0001 
   
Smoking    1∙40  1∙39‐1∙42  <0∙0001  Smoking  1∙41  1∙39‐1∙42  <0∙0001 
Alcohol    1∙30  1∙27‐1∙32  <0∙0001  Alcohol  1∙30  1∙27‐1∙32  <0∙0001 
Psoriasis    1∙28  1∙23‐1∙32  <0∙0001  Psoriasis  1∙25  1∙21‐1∙29  <0∙0001 
   
Socio‐economic status    Socio‐economic status 
    Lowest    0∙75  0∙74‐0∙77  <0∙0001      Lowest  0∙75  0∙74‐0∙77  <0∙0001 
    Below average    1∙00  0∙99‐1∙02  0∙5431      Below average  1∙01  0∙99‐1∙02  0∙4800 
    Average    Ref∙      Average  Ref∙ 
    Above average    0∙85  0∙84‐0∙86  <0∙0001      Above average  0∙85  0∙84‐0∙86  <0∙0001 
    Highest    0∙69  0∙68‐0∙70  <0∙0001      Highest  0∙69  0∙68‐0∙70  <0∙0001 
Anti‐hypertensive drugs    1∙43  1∙37‐1∙50  <0∙0001  Anti‐hypertensive drugs  1∙43  1∙37‐1∙49  <0∙0001 
Lipid‐lowering drugs    1∙34  1∙32‐1∙37  <0∙0001  Lipid‐lowering drugs  1∙34  1∙31‐1∙37  <0∙0001 
Systemic corticosteroids    1∙19  1∙17‐1∙21  <0∙0001  Systemic corticosteroids  1∙19  1∙75‐1∙21  <0∙0001 
Inhaled corticosteroids    1∙13  1∙11‐1∙15  <0∙0001  Inhaled corticosteroids  1∙13  1∙11‐1∙15  <0∙0001 
                                          
CI, confidence interval; CS, corticosteroids; HR, hazard ratio. 
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Figure 1. Nelson-Aalen cumulative hazards curves of the risk of type 2 diabetes by topical corticosteroid potency 
Figure legend: CS, corticosteroids. 
A. Cumulative hazards curves overall, where topical CS is modelled as a categorical exposure by potency 
B. Cumulative hazards curves in land-mark analysis, after 6 months after initial exposure, where topical CS is modelled as a categorical exposure by 
potency. 
 
 
Figure 2. Forest plot of hazard ratios for type 2 diabetes according to potency in different age-groups. 
Figure legend: CS, corticosteroids 
